AbbVie’s Rinvoq saw the highest use at the three-month post-launch mark in PsA. Even so, there are signs Bimzelx is affecting the PsA market. Attracted by the perceived efficacy of the drug’s ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.

to help offset the expected declines in Humira sales once biosimilar competition arrives in the US market, currently expected in 2023. By then, Rinvoq should be making upwards of $2 billion in ...